Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. These figures are ...

(RTTNews) - Novavax, Inc. (NVAX) reported net income for the first ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Novavax, Inc. (NASDAQ:NVAX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. Consensus estimates suggest investors could expect ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

ARGX is set to report earnings on May 8, before market open. Novavax NVAX has an Earnings ESP of +495.75% and a Zacks Rank #3 at present. NVAX is set to report earnings on May 8, before market open.

Novavax (NASDAQ:NVAX) pivots back to profitability after delivering a $666.7 million revenue haul in Q1surpassing estimates ...

Novavax (NASDAQ:NVAX) shares climbed ~35% in the premarket on Thursday after the COVID-19 vaccine maker lifted its full-year revenue outlook and reported Q1 2025 results significantly exceeding ...

Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.

Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (TAK).

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.